Blockade of NF-κB ameliorates myocardial hypertrophy in response to chronic infusion of angiotensin II

Shunichi Kawano, Toru Kubota, Yoshiya Monden, Natsumi Kawamura, Hiroyuki Tsutsui, Akira Takeshita, Kenji Sunagawa

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Objective: Nuclear factor (NF)-κB is a key transcription factor that regulates inflammatory processes. In the present study, we assessed the hypothesis that blockade of NF-κB may ameliorate ventricular hypertrophy in response to chronic infusion of angiotensin II. Methods: Mice with targeted disruption of the p50 subunit of NF-κB (KO) were used to block the activation of NF-κB. Male KO and age-matched wild-type (WT) mice were chronically infused with angiotensin II at the rate of 0.2 (low dose) or 2 μg/kg/min (high dose) for 4 weeks. Results: High- but not low-dose angiotensin II significantly increased systemic blood pressure and left ventricular weight in WT mice. In contrast, although the pressor response was slightly but significantly augmented, the hypertrophic effect of angiotensin II was significantly attenuated in KO mice. The attenuated hypertrophic responsiveness was confirmed histologically (cross-sectional area) and transcriptionally (atrial natriuretic peptide). Echocardiography revealed no evidence of cardiac dysfunction in angiotensin II-treated KO mice. Although phosphorylation of MAPKs, including ERK, JNK, or p38-MAPK, was not affected after 4 weeks of angiotensin II treatment in WT mice, phosphorylation of JNK was specifically abrogated in KO mice. Angiotensin II increased myocardial expression of proinflammatory cytokines and chemokines in WT mice, while expression of TNF-α and RANTES was paradoxically augmented in KO mice. Conclusion: Blockade of NF-κB activation attenuated myocardial hypertrophy without deteriorating cardiac function. NF-κB may play an important role in cardiac hypertrophy and remodeling besides promoting inflammation.

Original languageEnglish
Pages (from-to)689-698
Number of pages10
JournalCardiovascular research
Volume67
Issue number4
DOIs
Publication statusPublished - Sep 1 2005

Fingerprint

Angiotensin II
Hypertrophy
Phosphorylation
Chemokine CCL5
Cardiomegaly
Atrial Natriuretic Factor
p38 Mitogen-Activated Protein Kinases
Chemokines
Echocardiography
Transcription Factors
Cytokines
Blood Pressure
Inflammation
Weights and Measures

All Science Journal Classification (ASJC) codes

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Blockade of NF-κB ameliorates myocardial hypertrophy in response to chronic infusion of angiotensin II. / Kawano, Shunichi; Kubota, Toru; Monden, Yoshiya; Kawamura, Natsumi; Tsutsui, Hiroyuki; Takeshita, Akira; Sunagawa, Kenji.

In: Cardiovascular research, Vol. 67, No. 4, 01.09.2005, p. 689-698.

Research output: Contribution to journalArticle

Kawano, Shunichi ; Kubota, Toru ; Monden, Yoshiya ; Kawamura, Natsumi ; Tsutsui, Hiroyuki ; Takeshita, Akira ; Sunagawa, Kenji. / Blockade of NF-κB ameliorates myocardial hypertrophy in response to chronic infusion of angiotensin II. In: Cardiovascular research. 2005 ; Vol. 67, No. 4. pp. 689-698.
@article{c63d8edf7acc4183ab2488e27c8cddaa,
title = "Blockade of NF-κB ameliorates myocardial hypertrophy in response to chronic infusion of angiotensin II",
abstract = "Objective: Nuclear factor (NF)-κB is a key transcription factor that regulates inflammatory processes. In the present study, we assessed the hypothesis that blockade of NF-κB may ameliorate ventricular hypertrophy in response to chronic infusion of angiotensin II. Methods: Mice with targeted disruption of the p50 subunit of NF-κB (KO) were used to block the activation of NF-κB. Male KO and age-matched wild-type (WT) mice were chronically infused with angiotensin II at the rate of 0.2 (low dose) or 2 μg/kg/min (high dose) for 4 weeks. Results: High- but not low-dose angiotensin II significantly increased systemic blood pressure and left ventricular weight in WT mice. In contrast, although the pressor response was slightly but significantly augmented, the hypertrophic effect of angiotensin II was significantly attenuated in KO mice. The attenuated hypertrophic responsiveness was confirmed histologically (cross-sectional area) and transcriptionally (atrial natriuretic peptide). Echocardiography revealed no evidence of cardiac dysfunction in angiotensin II-treated KO mice. Although phosphorylation of MAPKs, including ERK, JNK, or p38-MAPK, was not affected after 4 weeks of angiotensin II treatment in WT mice, phosphorylation of JNK was specifically abrogated in KO mice. Angiotensin II increased myocardial expression of proinflammatory cytokines and chemokines in WT mice, while expression of TNF-α and RANTES was paradoxically augmented in KO mice. Conclusion: Blockade of NF-κB activation attenuated myocardial hypertrophy without deteriorating cardiac function. NF-κB may play an important role in cardiac hypertrophy and remodeling besides promoting inflammation.",
author = "Shunichi Kawano and Toru Kubota and Yoshiya Monden and Natsumi Kawamura and Hiroyuki Tsutsui and Akira Takeshita and Kenji Sunagawa",
year = "2005",
month = "9",
day = "1",
doi = "10.1016/j.cardiores.2005.04.030",
language = "English",
volume = "67",
pages = "689--698",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Blockade of NF-κB ameliorates myocardial hypertrophy in response to chronic infusion of angiotensin II

AU - Kawano, Shunichi

AU - Kubota, Toru

AU - Monden, Yoshiya

AU - Kawamura, Natsumi

AU - Tsutsui, Hiroyuki

AU - Takeshita, Akira

AU - Sunagawa, Kenji

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Objective: Nuclear factor (NF)-κB is a key transcription factor that regulates inflammatory processes. In the present study, we assessed the hypothesis that blockade of NF-κB may ameliorate ventricular hypertrophy in response to chronic infusion of angiotensin II. Methods: Mice with targeted disruption of the p50 subunit of NF-κB (KO) were used to block the activation of NF-κB. Male KO and age-matched wild-type (WT) mice were chronically infused with angiotensin II at the rate of 0.2 (low dose) or 2 μg/kg/min (high dose) for 4 weeks. Results: High- but not low-dose angiotensin II significantly increased systemic blood pressure and left ventricular weight in WT mice. In contrast, although the pressor response was slightly but significantly augmented, the hypertrophic effect of angiotensin II was significantly attenuated in KO mice. The attenuated hypertrophic responsiveness was confirmed histologically (cross-sectional area) and transcriptionally (atrial natriuretic peptide). Echocardiography revealed no evidence of cardiac dysfunction in angiotensin II-treated KO mice. Although phosphorylation of MAPKs, including ERK, JNK, or p38-MAPK, was not affected after 4 weeks of angiotensin II treatment in WT mice, phosphorylation of JNK was specifically abrogated in KO mice. Angiotensin II increased myocardial expression of proinflammatory cytokines and chemokines in WT mice, while expression of TNF-α and RANTES was paradoxically augmented in KO mice. Conclusion: Blockade of NF-κB activation attenuated myocardial hypertrophy without deteriorating cardiac function. NF-κB may play an important role in cardiac hypertrophy and remodeling besides promoting inflammation.

AB - Objective: Nuclear factor (NF)-κB is a key transcription factor that regulates inflammatory processes. In the present study, we assessed the hypothesis that blockade of NF-κB may ameliorate ventricular hypertrophy in response to chronic infusion of angiotensin II. Methods: Mice with targeted disruption of the p50 subunit of NF-κB (KO) were used to block the activation of NF-κB. Male KO and age-matched wild-type (WT) mice were chronically infused with angiotensin II at the rate of 0.2 (low dose) or 2 μg/kg/min (high dose) for 4 weeks. Results: High- but not low-dose angiotensin II significantly increased systemic blood pressure and left ventricular weight in WT mice. In contrast, although the pressor response was slightly but significantly augmented, the hypertrophic effect of angiotensin II was significantly attenuated in KO mice. The attenuated hypertrophic responsiveness was confirmed histologically (cross-sectional area) and transcriptionally (atrial natriuretic peptide). Echocardiography revealed no evidence of cardiac dysfunction in angiotensin II-treated KO mice. Although phosphorylation of MAPKs, including ERK, JNK, or p38-MAPK, was not affected after 4 weeks of angiotensin II treatment in WT mice, phosphorylation of JNK was specifically abrogated in KO mice. Angiotensin II increased myocardial expression of proinflammatory cytokines and chemokines in WT mice, while expression of TNF-α and RANTES was paradoxically augmented in KO mice. Conclusion: Blockade of NF-κB activation attenuated myocardial hypertrophy without deteriorating cardiac function. NF-κB may play an important role in cardiac hypertrophy and remodeling besides promoting inflammation.

UR - http://www.scopus.com/inward/record.url?scp=22744444997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22744444997&partnerID=8YFLogxK

U2 - 10.1016/j.cardiores.2005.04.030

DO - 10.1016/j.cardiores.2005.04.030

M3 - Article

C2 - 15921667

AN - SCOPUS:22744444997

VL - 67

SP - 689

EP - 698

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 4

ER -